Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05171049




Registration number
NCT05171049
Ethics application status
Date submitted
22/11/2021
Date registered
28/12/2021
Date last updated
31/10/2024

Titles & IDs
Public title
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
Scientific title
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE
Secondary ID [1] 0 0
2021-003076-14
Secondary ID [2] 0 0
ANT-007
Universal Trial Number (UTN)
Trial acronym
ASTER
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Venous Thromboembolism 0 0
Deep Venous Thrombosis 0 0
Pulmonary Embolism 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Blood 0 0 0 0
Clotting disorders
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Abelacimab
Treatment: Drugs - Apixaban

Experimental: Abelacimab - Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously

Active comparator: Apixaban - Apixaban administered orally twice a day


Treatment: Other: Abelacimab
Abelacimab 150 mg

Treatment: Drugs: Apixaban
Apixaban 10 mg followed by 5 mg
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out
Timepoint [1] 0 0
6 months
Secondary outcome [1] 0 0
Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding
Timepoint [2] 0 0
6 months

Eligibility
Key inclusion criteria
* Male or female subjects =18 years old or other legal maturity age according to the country of residence
* Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following:

* Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization and/or
* Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.
* Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery.

Patients are eligible within 120 hours from diagnosis of the qualifying VTE

* Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated
* Able to provide written informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE
* More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants
* An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)
* Platelet count <50,000/mm3 at the screening visit
* PE leading to hemodynamic instability (blood pressure [BP] <90 mmHg or shock)
* Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within the 4 weeks preceding screening
* Brain trauma or a cerebral or spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
* Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin
* Primary brain cancer or untreated intracranial metastases at baseline
* Acute myeloid or lymphoid leukemia
* Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
* Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
* Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening
* Life expectancy <3 months at randomization
* Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) at the screening visit
* Hemoglobin <8 g/dL at the screening visit
* Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase (ALT) =3 x and/or bilirubin =2 x upper limit of normal (ULN) at the screening visit in absence of clinical explanation
* Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
* Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab (See Section 5.3.6. for highly effective contraceptive measures)
* Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab
* Pregnant or breast-feeding women
* Patients known to be receiving strong dual inducers or inhibitors of both CYP3A4 and P gp
* History of hypersensitivity to any of the study drugs (including apixaban) or excipients, to drugs of similar chemical classes, or any contraindication listed in the label for apixaban
* Subjects with any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study
* Use of other investigational (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/05/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2027
Actual
Sample size
Target
1655
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Blacktown Hospital - Blacktown
Recruitment hospital [2] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [5] 0 0
Monash Medical Centre Clayton - Clayton
Recruitment hospital [6] 0 0
Northern Health - Epping
Recruitment hospital [7] 0 0
Perth Blood Institute - Perth
Recruitment hospital [8] 0 0
The Alfred Hospital - Prahran
Recruitment postcode(s) [1] 0 0
2148 - Blacktown
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3076 - Epping
Recruitment postcode(s) [7] 0 0
6005 - Perth
Recruitment postcode(s) [8] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Missouri
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oklahoma
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Texas
Country [17] 0 0
United States of America
State/province [17] 0 0
Virginia
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Austria
State/province [19] 0 0
Graz
Country [20] 0 0
Austria
State/province [20] 0 0
Neustadt
Country [21] 0 0
Austria
State/province [21] 0 0
Vienna
Country [22] 0 0
Canada
State/province [22] 0 0
Alberta
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
Canada
State/province [25] 0 0
Nova Scotia
Country [26] 0 0
Canada
State/province [26] 0 0
Québec
Country [27] 0 0
China
State/province [27] 0 0
Beijing
Country [28] 0 0
China
State/province [28] 0 0
Ch'ang-ch'un
Country [29] 0 0
China
State/province [29] 0 0
Guangdong
Country [30] 0 0
China
State/province [30] 0 0
Guangzhou
Country [31] 0 0
China
State/province [31] 0 0
Huizhou
Country [32] 0 0
China
State/province [32] 0 0
Nanjing
Country [33] 0 0
China
State/province [33] 0 0
Wenzhou
Country [34] 0 0
China
State/province [34] 0 0
Wuhan
Country [35] 0 0
China
State/province [35] 0 0
Xi'an
Country [36] 0 0
Czechia
State/province [36] 0 0
Brno
Country [37] 0 0
Czechia
State/province [37] 0 0
Hradec Kralove
Country [38] 0 0
Czechia
State/province [38] 0 0
Nová Ves Pod Pleší
Country [39] 0 0
Czechia
State/province [39] 0 0
Prague
Country [40] 0 0
Czechia
State/province [40] 0 0
Praha
Country [41] 0 0
France
State/province [41] 0 0
Amiens
Country [42] 0 0
France
State/province [42] 0 0
Angers
Country [43] 0 0
France
State/province [43] 0 0
Brest
Country [44] 0 0
France
State/province [44] 0 0
Clermont-Ferrand
Country [45] 0 0
France
State/province [45] 0 0
Colombes
Country [46] 0 0
France
State/province [46] 0 0
Dijon
Country [47] 0 0
France
State/province [47] 0 0
Grenoble
Country [48] 0 0
France
State/province [48] 0 0
Le Puy-en-Velay
Country [49] 0 0
France
State/province [49] 0 0
Limoges
Country [50] 0 0
France
State/province [50] 0 0
Marseille
Country [51] 0 0
France
State/province [51] 0 0
Morlaix
Country [52] 0 0
France
State/province [52] 0 0
Paris
Country [53] 0 0
France
State/province [53] 0 0
Pierre-Bénite
Country [54] 0 0
France
State/province [54] 0 0
Rouen
Country [55] 0 0
France
State/province [55] 0 0
Saint-Étienne
Country [56] 0 0
France
State/province [56] 0 0
Strasbourg
Country [57] 0 0
France
State/province [57] 0 0
Toulon
Country [58] 0 0
France
State/province [58] 0 0
Toulouse
Country [59] 0 0
France
State/province [59] 0 0
Vandœuvre-lès-Nancy
Country [60] 0 0
Germany
State/province [60] 0 0
Dresden
Country [61] 0 0
Germany
State/province [61] 0 0
Görlitz
Country [62] 0 0
Germany
State/province [62] 0 0
Hamburg
Country [63] 0 0
Germany
State/province [63] 0 0
Kiel
Country [64] 0 0
Germany
State/province [64] 0 0
Leipzig
Country [65] 0 0
Germany
State/province [65] 0 0
Magdeburg
Country [66] 0 0
Germany
State/province [66] 0 0
Muenchen
Country [67] 0 0
Hungary
State/province [67] 0 0
Budapest
Country [68] 0 0
Hungary
State/province [68] 0 0
Debrecen
Country [69] 0 0
Hungary
State/province [69] 0 0
Eger
Country [70] 0 0
Hungary
State/province [70] 0 0
Kecskemét
Country [71] 0 0
Hungary
State/province [71] 0 0
Pécs
Country [72] 0 0
Ireland
State/province [72] 0 0
Cork
Country [73] 0 0
Ireland
State/province [73] 0 0
Dublin
Country [74] 0 0
Ireland
State/province [74] 0 0
Limerick
Country [75] 0 0
Italy
State/province [75] 0 0
Bari
Country [76] 0 0
Italy
State/province [76] 0 0
Bergamo
Country [77] 0 0
Italy
State/province [77] 0 0
Bologna
Country [78] 0 0
Italy
State/province [78] 0 0
Castelfranco Veneto
Country [79] 0 0
Italy
State/province [79] 0 0
Chieti
Country [80] 0 0
Italy
State/province [80] 0 0
Cosenza
Country [81] 0 0
Italy
State/province [81] 0 0
Faenza
Country [82] 0 0
Italy
State/province [82] 0 0
Genova
Country [83] 0 0
Italy
State/province [83] 0 0
Grosseto
Country [84] 0 0
Italy
State/province [84] 0 0
Milano
Country [85] 0 0
Italy
State/province [85] 0 0
Modena
Country [86] 0 0
Italy
State/province [86] 0 0
Napoli
Country [87] 0 0
Italy
State/province [87] 0 0
Padova
Country [88] 0 0
Italy
State/province [88] 0 0
Parma
Country [89] 0 0
Italy
State/province [89] 0 0
Perugia
Country [90] 0 0
Italy
State/province [90] 0 0
Pisa
Country [91] 0 0
Italy
State/province [91] 0 0
Reggio Emilia
Country [92] 0 0
Italy
State/province [92] 0 0
Roma
Country [93] 0 0
Italy
State/province [93] 0 0
Rozzano
Country [94] 0 0
Italy
State/province [94] 0 0
Treviso
Country [95] 0 0
Italy
State/province [95] 0 0
Udine
Country [96] 0 0
Italy
State/province [96] 0 0
Varese
Country [97] 0 0
Italy
State/province [97] 0 0
Venezia
Country [98] 0 0
Italy
State/province [98] 0 0
Verduno
Country [99] 0 0
Italy
State/province [99] 0 0
Vicenza
Country [100] 0 0
Japan
State/province [100] 0 0
Tokyo
Country [101] 0 0
Japan
State/province [101] 0 0
Chiba
Country [102] 0 0
Japan
State/province [102] 0 0
Fukuoka
Country [103] 0 0
Japan
State/province [103] 0 0
Isehara
Country [104] 0 0
Japan
State/province [104] 0 0
Kanagawa
Country [105] 0 0
Japan
State/province [105] 0 0
Kobe
Country [106] 0 0
Japan
State/province [106] 0 0
Kumamoto
Country [107] 0 0
Japan
State/province [107] 0 0
Kyoto
Country [108] 0 0
Japan
State/province [108] 0 0
Mie
Country [109] 0 0
Japan
State/province [109] 0 0
Minato-Ku
Country [110] 0 0
Japan
State/province [110] 0 0
Miyagi
Country [111] 0 0
Japan
State/province [111] 0 0
Okayama
Country [112] 0 0
Japan
State/province [112] 0 0
Osaka
Country [113] 0 0
Korea, Republic of
State/province [113] 0 0
Gyeonggi-do
Country [114] 0 0
Korea, Republic of
State/province [114] 0 0
Anyang
Country [115] 0 0
Korea, Republic of
State/province [115] 0 0
Bucheon
Country [116] 0 0
Korea, Republic of
State/province [116] 0 0
Daegu
Country [117] 0 0
Korea, Republic of
State/province [117] 0 0
Gangdong
Country [118] 0 0
Korea, Republic of
State/province [118] 0 0
Jeonju
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Seogu
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Seoul
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Yangcheon
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Yongsan
Country [123] 0 0
Latvia
State/province [123] 0 0
Daugavpils
Country [124] 0 0
Latvia
State/province [124] 0 0
Liepaja
Country [125] 0 0
Latvia
State/province [125] 0 0
Riga
Country [126] 0 0
Netherlands
State/province [126] 0 0
Amersfoort
Country [127] 0 0
Netherlands
State/province [127] 0 0
Amsterdam
Country [128] 0 0
Netherlands
State/province [128] 0 0
Beverwijk
Country [129] 0 0
Netherlands
State/province [129] 0 0
Den Haag
Country [130] 0 0
Netherlands
State/province [130] 0 0
Dordrecht
Country [131] 0 0
Netherlands
State/province [131] 0 0
Groningen
Country [132] 0 0
Netherlands
State/province [132] 0 0
Hilversum
Country [133] 0 0
Netherlands
State/province [133] 0 0
Holland
Country [134] 0 0
Netherlands
State/province [134] 0 0
Hoofddorp
Country [135] 0 0
Netherlands
State/province [135] 0 0
Leiden
Country [136] 0 0
Netherlands
State/province [136] 0 0
Nijmegen
Country [137] 0 0
Netherlands
State/province [137] 0 0
Rotterdam
Country [138] 0 0
Norway
State/province [138] 0 0
Fredrikstad
Country [139] 0 0
Norway
State/province [139] 0 0
Lørenskog
Country [140] 0 0
Norway
State/province [140] 0 0
Oslo
Country [141] 0 0
Spain
State/province [141] 0 0
Barcelona
Country [142] 0 0
Spain
State/province [142] 0 0
Elche
Country [143] 0 0
Spain
State/province [143] 0 0
Granada
Country [144] 0 0
Spain
State/province [144] 0 0
Jaén
Country [145] 0 0
Spain
State/province [145] 0 0
Lugo
Country [146] 0 0
Spain
State/province [146] 0 0
Madrid
Country [147] 0 0
Spain
State/province [147] 0 0
Majadahonda
Country [148] 0 0
Spain
State/province [148] 0 0
Ourense
Country [149] 0 0
Spain
State/province [149] 0 0
Pamplona
Country [150] 0 0
Spain
State/province [150] 0 0
Sabadell
Country [151] 0 0
Spain
State/province [151] 0 0
Santander
Country [152] 0 0
Spain
State/province [152] 0 0
Santiago De Compostela
Country [153] 0 0
Spain
State/province [153] 0 0
Sevilla
Country [154] 0 0
Sweden
State/province [154] 0 0
Sundsvall
Country [155] 0 0
Switzerland
State/province [155] 0 0
Bern
Country [156] 0 0
Switzerland
State/province [156] 0 0
Geneve
Country [157] 0 0
Switzerland
State/province [157] 0 0
Lausanne
Country [158] 0 0
Switzerland
State/province [158] 0 0
Zürich
Country [159] 0 0
Taiwan
State/province [159] 0 0
Kaohsiung
Country [160] 0 0
Taiwan
State/province [160] 0 0
New Taipei City
Country [161] 0 0
Taiwan
State/province [161] 0 0
Taichung
Country [162] 0 0
Taiwan
State/province [162] 0 0
Tainan
Country [163] 0 0
Taiwan
State/province [163] 0 0
Taipei
Country [164] 0 0
United Kingdom
State/province [164] 0 0
England
Country [165] 0 0
United Kingdom
State/province [165] 0 0
ENG
Country [166] 0 0
United Kingdom
State/province [166] 0 0
SCO

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Anthos Therapeutics, Inc.
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Itreas
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Trial website
https://clinicaltrials.gov/study/NCT05171049
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Nancy Widener
Address 0 0
Country 0 0
Phone 0 0
239-284-3741
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05171049